Loading...
•
Sep 30
Krystal Biotech Q3 2025 Earnings Report
Krystal Biotech reported strong Q3 2025 results with significant revenue growth from VYJUVEK and expanded international launches.
Key Takeaways
Krystal Biotech delivered solid financial results for Q3 2025, driven by continued VYJUVEK revenue growth and expanded international reach. Net income more than doubled compared to the previous year, and the company ended the quarter with a robust cash position.
Generated $97.8 million in product revenue from VYJUVEK in Q3 2025.
Reported net income of $79.4 million and EPS of $2.74 (basic).
Launched VYJUVEK in Germany during Q3 and subsequently in France and Japan in Q4.
Ended Q3 with $864.2 million in cash and investments, supporting future pipeline growth.
Krystal Biotech
Krystal Biotech
Krystal Biotech Revenue by Segment
Krystal Biotech Revenue by Geographic Location
Revenue by Segment
VYJUVEK Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.com Forward Guidance
Krystal Biotech reaffirmed its non-GAAP expense guidance and highlighted multiple upcoming clinical data readouts, with a strong balance sheet supporting global expansion and pipeline growth.
Positive Outlook
- Strong cash position of $864.2 million to support operations and R&D.
- Global expansion of VYJUVEK into France and Japan underway.
- Upcoming CF (KB407) interim data expected in Q4 2025.
- Platform technology designation granted by FDA.
- Preparation for regulatory filings in the UK and Switzerland.
Challenges Ahead
- Pricing negotiations in Germany and France expected to extend into late 2026.
- No specific EPS guidance provided.
- Stock-based compensation not included in expense guidance, limiting GAAP comparability.
- Uncertain timelines for additional European launches outside Germany and France.
- Continued investment needed for global distributor network and expansion.